Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 0.98
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Data is available to registered users only
Target Price
Buy
Sell